Meds & supplements › Vadadustat
Medicine · Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Limitations of Use
The following clinically significant adverse reactions are discussed elsewhere in the labeling:
VAFSEO is contraindicated in patients:
Storage and Handling
sofidex [Internet]. Daloreum; c2026. Vadadustat; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/vadadustat
sofidex. (2026, August 3). Vadadustat. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/vadadustat
Vadadustat. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/vadadustat
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.